Skip to main content

Advertisement

SpringerLink
Log in

Adherence of Pharmacoeconomic Studies to National Guidelines in the Netherlands

  • Review Article
  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

Objective: This study examines the adherence of Dutch pharmacoeconomic studies to the national guidelines of conducting a pharmacoeconomic evaluation.

Methods: Dutch guidelines for pharmacoeconomic research were issued in 1999. All Dutch pharmacoeconomic studies that were published in English during 2000–2002 were selected for our review. Two reviewers examined each study for relevance and compared each study with the nine methodological guidelines selected.

Results: It was found that 29 studies satisfied the inclusion criteria. The societal perspective was taken in 13 out of the 29 studies (45%), an adequate time period of analysis was chosen in 21 (72%), effectiveness was explicitly differentiated from efficacy in 17 (59%), an incremental analysis was performed in 23 (79%), costs, benefits and health gains were discounted in 24 (83%), effectiveness was expressed in LYGs or QALYs in 16 (55%), reference prices were used in 8 (28%), subgroup analysis was presented in 13 (45%) and sensitivity analysis was included in 26 (90%).

Conclusions: In this review we found that the adherence of studies to some of the Dutch guidelines for pharmacoeconomic studies is fair. However, major improvements are required with respect to the adoption of the societal perspective, presentation of adequate subgroup analyses and application of reference prices.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. GO Delwel MJ Sprenger (2002) ArticleTitlePharmacoeconomic evaluations of new drugs: potential key to a more efficient allocation of the health care budget Ned Tijdschr Geneeskd 146 IssueID23 1068–71 Occurrence Handle12085554 Occurrence Handle1:STN:280:DC%2BD38zktlWjtg%3D%3D

    PubMed  CAS  Google Scholar 

  2. J Hjelmgren F Berggren F Andersson (2001) ArticleTitleHealth economic guidelines: similarities, differences and some implications Value Health 4 IssueID3 225–50 Occurrence Handle10.1046/j.1524-4733.2001.43040.x Occurrence Handle11705185 Occurrence Handle1:STN:280:DC%2BD3MnltFaktA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  3. InstitutionalAuthorNameCollege voor zorgverzekeringen (Health Care Insurance Board) (1999) Richtlijnen voor farmaco-economisch onderzoek. (Dutch guideline for pharmacoeconomic research) College voor zorgverzekeringen Amstelveen

    Google Scholar 

  4. MJ Nuijten MJ Brorens YA Hekster et al. (1998) ArticleTitleReporting format for economic evaluation. Part I: Application to the Dutch healthcare system Pharmacoeconomics 14 IssueID2 159–63 Occurrence Handle10186456 Occurrence Handle1:STN:280:DyaK1M%2Fit1ylsA%3D%3D

    PubMed  CAS  Google Scholar 

  5. MJ Nuijten MH Pronk MJ Brorens et al. (1998) ArticleTitleReporting formats for economic evaluation. Part II Focus on modelling studies Pharmacoeconomics 14 IssueID3 259–68 Occurrence Handle10186465 Occurrence Handle1:STN:280:DyaK1M%2Fit1yrug%3D%3D

    PubMed  CAS  Google Scholar 

  6. MJ Postma JJ Kwik WJ Rutten LTW Jong-van den Berg Particlede JRBJ Brouwers (2002) ArticleTitleOvereenkomsten tussen richtlijnen voor farmaco-economisch onderzoek en eerder gepubliceerde gezonheideconomische evaluaties [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations] Ned Tijdschr Geneeskd 146 IssueID23 1082–7 Occurrence Handle12085558 Occurrence Handle1:STN:280:DC%2BD38zktlWjug%3D%3D

    PubMed  CAS  Google Scholar 

  7. MJ Postma J Kruidhof LTW Jong-van den Berg Particlede JRBJ Brouwers (2002) ArticleTitleHet groeiende belang van kosteneffectiviteitsanalyses. Theorie en praktijk van het farmaco-economisch onderzoek (The increasing importance of cost effectiveness analysis. Theory and practice of pharmacoeconomic research) Pharmaceutisch Weekblad 137 IssueID45 1582–6

    Google Scholar 

  8. L Annemans JM Bos MJ Postma (2003) ArticleTitleDiscounting health effects in pharmaco-economic evaluations; some additional elements to consider ISPOR Connections 9 IssueID4 3–5

    Google Scholar 

  9. A Lazaro (2002) ArticleTitleTheoretical arguments for the discounting of health consequences. Where do we go from here? Pharmacoeconomics 20 IssueID14 943–61 Occurrence Handle12403636

    PubMed  Google Scholar 

  10. R Welte HH Konig R Leidl (2000) ArticleTitleThe costs of health damage and productivity losses attributable to cigarette smoking in Germany Eur J Public Health 10 IssueID1 31–8 Occurrence Handle10.1093/eurpub/10.1.31

    Article  Google Scholar 

  11. WJ Meerding M Ballegooijen ParticleVan MPM Burger et al. (2002) ArticleTitleHuman papillomavirus testing for triage of women referred because of abnormal smears: a decision analysis considering outcomes and costs J Clin Epidemiol 55 1025–32 Occurrence Handle10.1016/S0895-4356(02)00456-0 Occurrence Handle12464379

    Article  PubMed  Google Scholar 

  12. MA Koopmanschap FFH Rutten BM Ineveld ParticleVan et al. (1995) ArticleTitleThe friction cost method for measuring indirect cost of disease J Health Econ 14 171–89 Occurrence Handle10.1016/0167-6296(94)00044-5 Occurrence Handle10154656 Occurrence Handle1:STN:280:BymC2snmtFA%3D

    Article  PubMed  CAS  Google Scholar 

  13. BA Hout ParticleVan ML Simoons (2001) ArticleTitleCost effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J 22 IssueID9 751–61 Occurrence Handle11350107

    PubMed  Google Scholar 

  14. M Akazawa JL Sindelar D Paltiel (2003) ArticleTitleEconomic costs of influenza-related work absenteism Value Health 6 107–15 Occurrence Handle10.1046/j.1524-4733.2003.00209.x Occurrence Handle12641861

    Article  PubMed  Google Scholar 

  15. InstitutionalAuthorNameCollege voor zorgverzekeringen (Health Care Insurance Board) (2001) Farmacotherapeutisch Kompas 2002 (Pharmacotherapeutic Compass) College voor Zorgverzekeringen Amstelveen

    Google Scholar 

  16. R Welte M Kretzschmar R Leidl et al. (2000) ArticleTitleCost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach Sex Transm Dis 27 IssueID9 518–29 Occurrence Handle11034526 Occurrence Handle1:STN:280:DC%2BD3cvosFyltA%3D%3D

    PubMed  CAS  Google Scholar 

  17. JB Oostenbrink MA Koopmanschap FFH Rutten (2000) Handleiding voor kostenonderzoek; methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg [Guidelines for costing research methods and reference prices for economic evaluation in health care] College voor zorgverzekeringen Amstelveen

    Google Scholar 

  18. N Os ParticleVan LW Niessen HJ Bilo et al. (2000) ArticleTitleDiabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines Health Policy 51 IssueID3 135–47 Occurrence Handle10720684

    PubMed  Google Scholar 

  19. EA Stolk JJV Busschbach M Caffa et al. (2000) ArticleTitleCost utility analysis of sildenafil compared with papaverine-phentolamine injections BMJ 320 1165 Occurrence Handle10.1136/bmj.320.7243.1165 Occurrence Handle10784537 Occurrence Handle1:STN:280:DC%2BD3c3kslSguw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  20. EA Joosen JH Reininga JM Manders et al. (2000) ArticleTitleCosts and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice Eur J Gastroenterol Hepatol 12 IssueID3 319–25 Occurrence Handle10750653 Occurrence Handle1:STN:280:DC%2BD3c3ht1Kqsw%3D%3D Occurrence Handle10.1097/00042737-200012030-00010

    Article  PubMed  CAS  Google Scholar 

  21. MJ Postma ML Heijnen JC Jager (2001) ArticleTitleCost-effectiveness analysis of pneumococcal vaccination for elderly individuals in the Netherlands Pharmacoeconomics 19 IssueID2 215–22 Occurrence Handle11284385 Occurrence Handle1:STN:280:DC%2BD3M3ivVahtQ%3D%3D

    PubMed  CAS  Google Scholar 

  22. CG Pinto A Lafuma F Fagnani et al. (2001) ArticleTitleCost-effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries Pharmacoeconomics 19 IssueID3 255–65 Occurrence Handle11303414 Occurrence Handle1:CAS:528:DC%2BD3MXitlKhur0%3D

    PubMed  CAS  Google Scholar 

  23. JM Bos JS Fennema MJ Postma (2001) ArticleTitleCost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam AIDS 15 IssueID15 2031–6 Occurrence Handle10.1097/00002030-200110190-00017 Occurrence Handle11600833 Occurrence Handle1:STN:280:DC%2BD3Mrltlehug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  24. JM Bos HC Rümke R Welte et al. (2001) ArticleTitleHealth economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program Vaccine 20 IssueID1–2 202–7 Occurrence Handle11567765 Occurrence Handle1:STN:280:DC%2BD3Mrit1Ojsw%3D%3D

    PubMed  CAS  Google Scholar 

  25. MJ Nuijten P Iperen Particlevan C Palmer et al. (2001) ArticleTitleCost-effectiveness analysis of entacapone in Parkinson’s disease: a Markov process analysis Value Health 4 IssueID4 316–28 Occurrence Handle11705299 Occurrence Handle1:STN:280:DC%2BD3MnltFaluw%3D%3D

    PubMed  CAS  Google Scholar 

  26. R Jansen WK Redekop FF Rutten (2001) ArticleTitleCost-effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON study Lamisil versus Itraconazole in Onychomycosis Pharmacoeconomics 19 IssueID4 401–10 Occurrence Handle11383756 Occurrence Handle1:STN:280:DC%2BD3MzhtFaksw%3D%3D

    PubMed  CAS  Google Scholar 

  27. JJ Doyle J Casciano S Arikian et al. (2001) ArticleTitleA multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs Value Health 4 IssueID1 16–31 Occurrence Handle10.1046/j.1524-4733.2001.004001016.x Occurrence Handle11704969 Occurrence Handle1:STN:280:DC%2BD3MnltFartg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  28. E Müller MW Leen Particlevan R Bergemann (2001) ArticleTitleEconomic evaluation of collagenase-containing ointment and hydrocolloid dressing in the treatment of pressure ulcers Pharmacoeconomics 19 IssueID12 1209–16 Occurrence Handle11772156

    PubMed  Google Scholar 

  29. IGM Valkengoed ParticleVan MJ Postma SA Morré et al. (2001) ArticleTitleCost-effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens Sex Transm Inf 77 276–82

    Google Scholar 

  30. P Krijnen CJE Kaandorp EW Steyerberg et al. (2001) ArticleTitleAntibiotic prophylaxis for haematogenous bacterial arthritis in-patients with joint disease: a cost effectiveness analysis Ann Rheum Dis 60 359–66 Occurrence Handle10.1136/ard.60.4.359 Occurrence Handle11247866 Occurrence Handle1:STN:280:DC%2BD3M3gslKjtA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  31. G Boom ParticleVan den MPMH Rutten-van Mölken J Molema et al. (2001) ArticleTitleThe Cost-effectiveness of early treatment with Fluticasone propionate 250 μg twice a day in subjects with obstructive airway disease. Results of the DIMCA Program Am J Respir Crit Care Med 164 2057–66 Occurrence Handle11739135

    PubMed  Google Scholar 

  32. MJ Nuijten (2001) ArticleTitleAssessment of clinical guidelines for continuation treatment in major depression Value Health 4 IssueID4 281–94 Occurrence Handle11705296 Occurrence Handle1:STN:280:DC%2BD3MnltFaltA%3D%3D

    PubMed  CAS  Google Scholar 

  33. MJ Postma R Welte JA Hoek Particlevan den et al. (2001) ArticleTitleCost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis Value Health 4 IssueID3 266–75 Occurrence Handle10.1046/j.1524-4733.2001.43009.x Occurrence Handle11705188 Occurrence Handle1:STN:280:DC%2BD3MnltFakuw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  34. GH Bock ParticleDe AR Erkel Particlevan MP Springer J Kievit (2001) ArticleTitleAntibiotic prescription for acute sinusitis in otherwise healthy adults. Clinical cure in relation to costs Scand J Prim Health Care 19 IssueID1 58–63 Occurrence Handle11303550

    PubMed  Google Scholar 

  35. MJ Nuijten P Engelfriet K Duijn et al. (2001) ArticleTitleA cost–cost study comparing etanercept with infliximab in rheumatoid arthritis Pharmacoeconomics 19 IssueID10 1051–64 Occurrence Handle11735673 Occurrence Handle1:STN:280:DC%2BD38%2Fjtlaqsw%3D%3D

    PubMed  CAS  Google Scholar 

  36. N Li M Agthoven Particlevan P Willemse C Uyl-de Groot (2001) ArticleTitleA cost-utility analysis comparing second-line chemotherapy schemes in-patients with metastatic breast cancer Anticancer Drugs 12 IssueID6 533–40 Occurrence Handle10.1097/00001813-200107000-00007 Occurrence Handle11460000 Occurrence Handle1:CAS:528:DC%2BD3MXlvFersbg%3D

    Article  PubMed  CAS  Google Scholar 

  37. JB Oostenbrink MJD Tangelder JJV Busschbach et al. (2001) ArticleTitleCost-effectiveness of oral anticoagulant versus aspirin in-patients after infrainguinal bypass grafting surgery Vasc Surg 34 254–62 Occurrence Handle1:STN:280:DC%2BD3MvltVeltQ%3D%3D

    CAS  Google Scholar 

  38. P Lindgren B Jönsson A Redaelli D Radice (2002) ArticleTitleCost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia Pharmacoeconomics 20 IssueID2 101–8 Occurrence Handle11888362 Occurrence Handle1:CAS:528:DC%2BD38XjtFKjtrw%3D

    PubMed  CAS  Google Scholar 

  39. M Hartman M Prins OQ Swinkels et al. (2002) ArticleTitleCost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment Br J Dermatol 147 IssueID3 538–44 Occurrence Handle10.1046/j.1365-2133.2002.04920.x Occurrence Handle12207597 Occurrence Handle1:STN:280:DC%2BD38vltlSmtw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  40. MJ Postma J Londeman M Veenstra et al. (Feb 2002) ArticleTitleCost-effectiveness of periconceptional supplementation of folic acid Pharm World Sci 24 IssueID1 8–11 Occurrence Handle10.1023/A:1014848928212

    Article  Google Scholar 

  41. JM Ten Berg JC Kelder TH Plokker BA Hout Particlevan (2002) ArticleTitleCosts and effectiveness of using coumarins before, during and after coronary angioplasty Pharmacoeconomics 20 IssueID12 847–53 Occurrence Handle12236806

    PubMed  Google Scholar 

  42. JJ Caro M Salas A Ward D Getsios A Mehnert (2002) ArticleTitleAHEAD Study Group. Assessment of Health Economics in Alzheimer’s Disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in the Netherlands Dement Geriatr Cogn Disord 14 IssueID2 84–9 Occurrence Handle10.1159/000064929 Occurrence Handle12145455 Occurrence Handle1:CAS:528:DC%2BD38Xls1Oru7o%3D

    Article  PubMed  CAS  Google Scholar 

  43. TR Schermer BP Thoonen G Boom Particlevan den et al. (2002) ArticleTitleRandomized Controlled Economic Evaluation of Asthma Self-Management in Primary Health Care Am J Respir Crit Care Med 166 1062–72 Occurrence Handle10.1164/rccm.2105116 Occurrence Handle12379549

    Article  PubMed  Google Scholar 

  44. M Agthoven ParticleVan CA Uyl-de Groot WJ Fokkens et al. (2002) ArticleTitleCost analysis of regular and filgrastim treatment in-patients with refractory chronic rhinosinusitis Rhinology 40 IssueID2 69–74 Occurrence Handle12091996

    PubMed  Google Scholar 

  45. Canadian Coordinating Office for Health Care Technology Assessment. Guideline for economic evaluation of pharmaceuticals: Canada. 1997. Ontario, Canada

  46. WJ Edmunds GF Medley DJ Nokes (1999) ArticleTitleEvaluating the cost effectiveness of vaccination programmes: a dynamic perspective Stat Med 18 3263–82 Occurrence Handle10.1002/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3 Occurrence Handle10602150 Occurrence Handle1:STN:280:DC%2BD3c%2FntValsA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  47. JF Baladi D Menon N Otten (1998) ArticleTitleUse of economic evaluation guidelines: 2 year’s experience in Canada Health Econ 7 221–7 Occurrence Handle10.1002/(SICI)1099-1050(199805)7:3<221::AID-HEC341>3.0.CO;2-N Occurrence Handle9639335 Occurrence Handle1:STN:280:DyaK1czgtFajtA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  48. InstitutionalAuthorNameAustralian Commonwealth Department of Health and Ageing (2002) Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee Commonwealth Department of Health and Ageing Canberra

    Google Scholar 

  49. InstitutionalAuthorNameOntario Ministry of Health and Long Term Care (1994) Ontario guidelines for economic analysis of pharmaceutical products Ontario-Ministry of Health and Long Term Care Toronto

    Google Scholar 

  50. AH Anis Y Gagnon (2000) ArticleTitleUsing economic evaluations to make formulary coverage decisions. So much for guidelines Pharmacoeconomics 18 IssueID1 55–62 Occurrence Handle11010604 Occurrence Handle1:STN:280:DC%2BD3M%2Fgs1ersg%3D%3D

    PubMed  CAS  Google Scholar 

  51. JL Severens (2001) ArticleTitleEconomic evaluation in health care: the usefulness of research guidelines Eur J Obst Gyn Reprod Biol 94 5–7 Occurrence Handle1:STN:280:DC%2BD3M7jtlahtA%3D%3D

    CAS  Google Scholar 

  52. Harrison DL. Evaluation and interpretation of pharmacoeconomic literature. www.oupharmacy.com/clinicaladmin/dharrison/coursenotes2/pharmecon_lit_eval.ppt.

Download references

Author information

Authors and Affiliations

  1. Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen University Institute for Drug Exploration (GUIDE), A. Deusinglaan 1, 9713, AV, Groningen, The Netherlands

    Jarir Atthobari, Jasper M. Bos, Cornelis Boersma, Jacobus R. B. J. Brouwers, Lolkje T. W. de Jong-van den Berg & Maarten J. Postma

Authors
  1. Jarir Atthobari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jasper M. Bos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cornelis Boersma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacobus R. B. J. Brouwers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lolkje T. W. de Jong-van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maarten J. Postma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maarten J. Postma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atthobari, J., Bos, J.M., Boersma, C. et al. Adherence of Pharmacoeconomic Studies to National Guidelines in the Netherlands. Pharm World Sci 27, 364–370 (2005). https://doi.org/10.1007/s11096-005-7904-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-005-7904-y

Key words

Search

Navigation